UCB BioSciences GmbH
🇩🇪Germany
A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 87
- Registration Number
- NCT01711866
- Locations
- 🇰🇷
106, Seoul, Korea, Republic of
🇰🇷102, Busan, Korea, Republic of
🇺🇸505, Anniston, Alabama, United States
A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease
- First Posted Date
- 2012-07-09
- Last Posted Date
- 2012-10-30
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Registration Number
- NCT01635621
Pediatric Arthritis Study of Certolizumab Pegol
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 193
- Registration Number
- NCT01550003
- Locations
- 🇺🇸
Ra0043 79, Los Angeles, California, United States
🇺🇸Ra0043 82, Chicago, Illinois, United States
🇺🇸Ra0043 85, New Hyde Park, New York, United States
A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT01537042
- Locations
- 🇺🇸
603, West Seneca, New York, United States
🇺🇸601, Austin, Texas, United States
🇫🇮201, Helsinki, Finland
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 551
- Registration Number
- NCT01465997
- Locations
- 🇫🇮
205, Helsinki, Finland
🇦🇺105, Clayton, Australia
🇺🇸794, Oklahoma City, Oklahoma, United States
Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 81
- Registration Number
- NCT01455012
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 888
- Registration Number
- NCT01243177
- Locations
- 🇺🇸
881, Mansfield, Texas, United States
🇩🇪263, Altenburg, Germany
🇩🇪260, Göttingen, Germany
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 325
- Registration Number
- NCT01087762
- Locations
- 🇺🇸
964, Hagerstown, Maryland, United States
🇺🇸975, Dallas, Texas, United States
🇨🇦907, Victoria, British Columbia, Canada
Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 409
- Registration Number
- NCT01087788
- Locations
- 🇵🇱
456, Warszawa, Poland
🇨🇿501, Hlucin, Czechia
🇧🇷761, Goiâna, Brazil
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 840
- Registration Number
- NCT00596752
- Locations
- 🇨🇿
414, Usti Nad Labem, Czechia
🇨🇿404, Plzen, Czechia
🇲🇽505, Merida, Mexico
© Copyright 2024. All Rights Reserved by MedPath